The use of atypical antipsychotics in French psychiatric hospitals

被引:6
作者
Bret, Marie Christine
Bret, Pierre
Pariente, Antoine
Fourier-Reglat, Annie
机构
[1] Ctr Hosp Charles Perrens, Dept Pharm, F-33076 Bordeaux, France
[2] Univ Bordeaux 2, IFR 99, EA 3676, Dept Pharmacol, F-33076 Bordeaux, France
来源
PHARMACY WORLD & SCIENCE | 2007年 / 29卷 / 05期
关键词
atypical antipsychotics; France; guidelines; hospital pharmacy; prescribing; psychiatry;
D O I
10.1007/s11096-007-9107-1
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
To study the prescribing practices of atypical antipsychotic drugs in French psychiatric hospitals. A 1-day cross-sectional observational survey was performed in seven psychiatric hospitals to study prescribing practices of the four atypical antipsychotics (AAP) marketed in France. These hospitals are members of the PIC network, a pharmacists' working group based in southwestern France. Type and dosages of prescribed atypical antipsychotics, indication and concomitant prescriptions. The study included 1475 adult inpatients' prescriptions with an antipsychotic drug; 647 prescriptions included an AAP with risperidone and olanzapine accounting for about 70% cases. AAP prescriptions concerned psychotic patients in 65% of cases. Patients receiving an AAP in this indication were more likely to be male, were younger, and received higher daily doses than patients treated for other troubles. They were also more likely to receive associated neuroleptic and anticholinergic antiparkinsonian agents. There were 59 prescriptions (9.1%) for bipolar disorders. Clozapine wasn't used in this indication. In 76.3% of cases, mood stabilizers were associated to the AAP prescribed in this indication. This observational survey underlines the significant place taken by AAP for the treatment of psychiatric diseases in hospital prescribing practices. They show usage patterns of these drugs: dose, indications and concomitant medications, in line or not with current recommendations and reference guidelines. In bipolar disorders, AAPs seem more likely to be associated to an ongoing therapy using mood stabilizer than to replace it.
引用
收藏
页码:551 / 556
页数:6
相关论文
共 20 条
  • [1] ALMARIC EF, 1998, PHARM HOSP FRANCAISE, V124, P69
  • [2] *ANDEM, 1997, CONCOURS MED, V119, P1441
  • [3] *APA, 1997, AM J PSYCH S, V4, P154
  • [4] AUGRY F, 2001, NERVURE, V4, P7
  • [5] Bret P, 2002, ENCEPHALE, V28, P329
  • [6] Brunot A, 2002, ENCEPHALE, V28, P129
  • [7] *COLL QUEB CLIN, 1999, SCHIZ TREATM
  • [8] *COLL WORK GROUP C, 1998, J CLIN PSYCHIAT S12, V59
  • [9] Patterns of neuroleptic drug prescription:: a national cross-sectional survey of a random sample of French psychiatrists
    Fourrier, A
    Gasquet, I
    Allicar, MP
    Bouhassira, M
    Lépine, JP
    Bégaud, B
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 49 (01) : 80 - 86
  • [10] GURY C, 2002, INFORM PSYCHIAT, V8, P954